Evidence map›Paper›PMID 39624057›Full record

ArticleMolecular therapy. Oncology2024

The YAP1-MAML2 fusion drives tumorigenesis and sustains tumor growth.

Wei Ni, Mu Yu, Rongqiang Yang, Jennifer W Li, Xin Zhou, Ozlem Calbay, Liya Pi, Jianrong Lu, Shuang Huang, Lizi Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. NovelCancers · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Wei NiDepartment of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL 32610, USA.
Mu YuDepartment of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL 32610, USA.
Rongqiang YangDepartment of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL 32610, USA.
Jennifer W LiDepartment of Medicine, Brown University, Providence, RI 02912, USA.
Xin ZhouDepartment of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL 32610, USA.
Ozlem CalbayUF Health Cancer Center, University of Florida, Gainesville, FL 32610, USA.
Liya PiDepartment of Pathology and Laboratory Medicine, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Jianrong LuUF Health Cancer Center, University of Florida, Gainesville, FL 32610, USA.
Shuang HuangUF Health Cancer Center, University of Florida, Gainesville, FL 32610, USA.
Lizi WuDepartment of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL 32610, USA.

Funding

Signaling and Targeting of CRTC1-MAML2 Fusion Oncoprotein in Salivary Gland TumorR01DE023641 · NIDCR · UNIVERSITY OF FLORIDA · PI Lizi Wu · 2014 to 2026
$3.3M
Aberrant CRTC activation as a unique vulnerability of lung cancer with LKB1 inactivationR01CA234351 · NCI · UNIVERSITY OF FLORIDA · PI WU, LIZI · 2019 to 2023
$1.7M
NCI NIH HHS R01 CA234351NIDCR NIH HHS R01 DE023641
6 · The paper itself

Abstract

The Yes1-associated transcriptional regulator-mastermind-like transcriptional co-activator 2 (YAP1-MAML2 [YM]) fusion protein arises from an intrachromosomal inversion and is implicated in various cancers. However, the oncogenic role of the endogenous YM fusion protein remained undefined. In this study, we employed YM-positive ES-2 ovarian cancer cells as a model to explore the roles of the YM fusion in cancer initiation and maintenance. The YM fusion protein localizes to nuclear speckles and contains bifunctional domains: the YAP1 N-terminal domain interacts with transcriptional enhanced associate domain (TEAD) transcription factors, while the MAML2 C-terminal domain activates YAP1/TEAD-driven transcription. YM exhibited transforming activity, as shown by its ability to induce focus formation in immortalized epithelial cells. YM depletion reduced cancer cell proliferation and survival both

Indexed as

fusion oncogeneoncogenesisTEAD/YAP1 transcriptiontherapeutic targetYAP1-MAML2 fusion

Identifiers

PMID39624057
PMCPMC11609529

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.